An observational study in Infertility, Female, sponsored by Organon and Co. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2022-02-03.
Sponsored by Organon and Co · Observational
This observational study will examine the safety and efficacy profile of Elonva (corifollitropin alfa) when administered in Korean women undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles in an assisted reproductive technology (ART) program.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 472 is above the median of 200 across 714 observational studies indexed under Infertility.
Browse Infertility studies →Organon and Co is the lead sponsor of 478 studies on the registry; none are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 17 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women participating in an ART program consisting of COS in combination with a GnRH antagonist in a general clinical setting.
Exclusion Criteria:
Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
Drug: corifollitropin alfa
100 or 150 microgram single subcutaneous injection
Also known as: Elonva
Number of Oocytes Retrieved
Time frame: At time of oocyte retrieval (up 3 days from human chorionic gonadotropin [hCG] injection)
Number of Participants who Experience Ovarian Hyperstimulation Syndrome (OHSS)
Time frame: During treatment and up to 30 days after cessation of treatment
Number of Participants who report an serious adverse event (SAE)
Time frame: During treatment and up to 30 days after cessation of treatment
Number of Participants who report an adverse event (AE)
Time frame: During treatment and up to 30 days after cessation of treatment
No study locations are listed for this record.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Organon and Co